These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 28830741)

  • 21. An increase in plasma brain derived neurotrophic factor levels is related to n-3 polyunsaturated fatty acid efficacy in first episode schizophrenia: secondary outcome analysis of the OFFER randomized clinical trial.
    Pawełczyk T; Grancow-Grabka M; Trafalska E; Szemraj J; Żurner N; Pawełczyk A
    Psychopharmacology (Berl); 2019 Sep; 236(9):2811-2822. PubMed ID: 31098654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of randomized supplementation with high dose olive, flax or fish oil on serum phospholipid fatty acid levels in adults with attention deficit hyperactivity disorder.
    Young GS; Conquer JA; Thomas R
    Reprod Nutr Dev; 2005; 45(5):549-58. PubMed ID: 16188207
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation.
    da Silva TM; Munhoz RP; Alvarez C; Naliwaiko K; Kiss A; Andreatini R; Ferraz AC
    J Affect Disord; 2008 Dec; 111(2-3):351-9. PubMed ID: 18485485
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: results from a randomized, placebo-controlled trial.
    Emsley R; Niehaus DJ; Oosthuizen PP; Koen L; Ascott-Evans B; Chiliza B; van Rensburg SJ; Smit RM
    Psychiatry Res; 2008 Dec; 161(3):284-91. PubMed ID: 18962989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-Chain Omega-3 Fatty Acid Supplements in Depressed Heart Failure Patients: Results of the OCEAN Trial.
    Jiang W; Whellan DJ; Adams KF; Babyak MA; Boyle SH; Wilson JL; Patel CB; Rogers JG; Harris WS; O'Connor CM
    JACC Heart Fail; 2018 Oct; 6(10):833-843. PubMed ID: 30098961
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia.
    Davidson M; Saoud J; Staner C; Noel N; Luthringer E; Werner S; Reilly J; Schaffhauser JY; Rabinowitz J; Weiser M; Luthringer R
    Am J Psychiatry; 2017 Dec; 174(12):1195-1202. PubMed ID: 28750582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nutrient supplementation with polyunsaturated fatty acids and micronutrients in rheumatoid arthritis: clinical and biochemical effects.
    Remans PH; Sont JK; Wagenaar LW; Wouters-Wesseling W; Zuijderduin WM; Jongma A; Breedveld FC; Van Laar JM
    Eur J Clin Nutr; 2004 Jun; 58(6):839-45. PubMed ID: 15164103
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized, placebo-controlled clinical trial of omega-3 as supplemental treatment in schizophrenia.
    Jamilian H; Solhi H; Jamilian M
    Glob J Health Sci; 2014 Sep; 6(7 Spec No):103-8. PubMed ID: 25363186
    [TBL] [Abstract][Full Text] [Related]  

  • 29. No effect of n-3 fatty acids on high-sensitivity C-reactive protein after myocardial infarction: the Alpha Omega Trial.
    Hoogeveen EK; Geleijnse JM; Kromhout D; Giltay EJ
    Eur J Prev Cardiol; 2014 Nov; 21(11):1429-36. PubMed ID: 23774275
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Omega-3 fatty acid supplementation may prevent loss of gray matter thickness in the left parieto-occipital cortex in first episode schizophrenia: A secondary outcome analysis of the OFFER randomized controlled study.
    Pawełczyk T; Piątkowska-Janko E; Bogorodzki P; Gębski P; Grancow-Grabka M; Trafalska E; Żurner N; Pawełczyk A
    Schizophr Res; 2018 May; 195():168-175. PubMed ID: 29079060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Similar eicosapentaenoic acid and docosahexaenoic acid plasma levels achieved with fish oil or krill oil in a randomized double-blind four-week bioavailability study.
    Yurko-Mauro K; Kralovec J; Bailey-Hall E; Smeberg V; Stark JG; Salem N
    Lipids Health Dis; 2015 Sep; 14():99. PubMed ID: 26328782
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Consumption of echium oil increases EPA and DPA in blood fractions more efficiently compared to linseed oil in humans.
    Kuhnt K; Weiß S; Kiehntopf M; Jahreis G
    Lipids Health Dis; 2016 Feb; 15():32. PubMed ID: 26892399
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of fish oil on cognitive performance in older subjects: a randomized, controlled trial.
    van de Rest O; Geleijnse JM; Kok FJ; van Staveren WA; Dullemeijer C; Olderikkert MG; Beekman AT; de Groot CP
    Neurology; 2008 Aug; 71(6):430-8. PubMed ID: 18678826
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polyunsaturated fatty acid supplementation for drug-resistant epilepsy.
    Sarmento Vasconcelos V; Macedo CR; de Souza Pedrosa A; Pereira Gomes Morais E; Porfírio GJ; Torloni MR
    Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD011014. PubMed ID: 27536971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia.
    Peet M; Brind J; Ramchand CN; Shah S; Vankar GK
    Schizophr Res; 2001 Apr; 49(3):243-51. PubMed ID: 11356585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The differential effects of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on seizure frequency in patients with drug-resistant epilepsy - A randomized, double-blind, placebo-controlled trial.
    Ibrahim FAS; Ghebremeskel K; Abdel-Rahman ME; Ahmed AAM; Mohmed IM; Osman G; Elseed M; Hamed A; Rabinowicz AL; Salih MAM; Elbashir MI; Daak AA
    Epilepsy Behav; 2018 Oct; 87():32-38. PubMed ID: 30170260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cognitive assessment of children at age 2(1/2) years after maternal fish oil supplementation in pregnancy: a randomised controlled trial.
    Dunstan JA; Simmer K; Dixon G; Prescott SL
    Arch Dis Child Fetal Neonatal Ed; 2008 Jan; 93(1):F45-50. PubMed ID: 17185423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is violence at presentation by patients with first-episode psychosis associated with duration of untreated psychosis?
    Foley SR; Browne S; Clarke M; Kinsella A; Larkin C; O'Callaghan E
    Soc Psychiatry Psychiatr Epidemiol; 2007 Aug; 42(8):606-10. PubMed ID: 17598060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Telomerase level increase is related to n-3 polyunsaturated fatty acid efficacy in first episode schizophrenia: Secondary outcome analysis of the OFFER randomized clinical trial.
    Pawełczyk T; Grancow-Grabka M; Trafalska E; Szemraj J; Żurner N; Pawełczyk A
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Apr; 83():142-148. PubMed ID: 29241838
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Raloxifene Plus Antipsychotics Versus Placebo Plus Antipsychotics in Severely Ill Decompensated Postmenopausal Women With Schizophrenia or Schizoaffective Disorder: A Randomized Controlled Trial.
    Weiser M; Levi L; Burshtein S; Hagin M; Matei VP; Podea D; Micluția I; Tiugan A; Păcală B; Grecu IG; Noy A; Zamora D; Davis JM
    J Clin Psychiatry; 2017 Jul; 78(7):e758-e765. PubMed ID: 28541645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.